Evogene Ltd. | CIK:0001574565 | 3

  • Filed: 3/30/2018
  • Entity registrant name: Evogene Ltd. (CIK: 0001574565)
  • Generator: GoXBRL
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1574565/000117891318001042/0001178913-18-001042-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1574565/000117891318001042/evgn-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001574565
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory

    NOTE 16: -     COMMITMENTS AND CONTINGENT LIABILITIES

    a.
    The Company leases facilities for its offices and research and development activities, as well as motor vehicles under operating leases. Future minimum lease payments under non-cancelable operating leases for the years ended December 31, are as follows:
     
    2018
     
    $
    742
     
    2019
       
    278
     
    2020
       
    285
     
    2021
       
    243
     
             
       
    $
    1,548
     
     
    The Company has provided bank guarantees in the amount of $304 to secure compliance with its facilities rental payment requirements.

    b.
    Claims

    As of December 31, 2017, the Company is not involved in any claims.

    c.
    Government grants

    The Company received research and development grants from the IIA, BIRD and CIIRDF, see note 12. If no economic benefits are expected from the research activity, the royalty obligation is not recorded as a liability and instead is treated as a contingent liability in accordance with IAS 37. The grants from the IIA impose certain restrictions on the transfer outside of Israel of the underlying know-how and the manufacturing or manufacturing rights of the underlying products and technologies.